Share on StockTwits

Medivation (NASDAQ:MDVN)‘s stock had its “positive” rating restated by equities research analysts at Jefferies Group in a research note issued to investors on Monday.

In other Medivation news, Insider Lynn Seely unloaded 20,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $83.62, for a total value of $1,672,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of other analysts have also recently weighed in on MDVN. Analysts at Aegis raised their price target on shares of Medivation from $125.00 to $130.00 in a research note on Friday, August 8th. Separately, analysts at Leerink Swann raised their price target on shares of Medivation from $104.00 to $107.00 in a research note on Friday, August 8th. Finally, analysts at Keefe, Bruyette & Woods reiterated an “outperform” rating on shares of Medivation in a research note on Friday, August 8th. They now have a $107.00 price target on the stock, up previously from $104.00. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $97.50.

Shares of Medivation (NASDAQ:MDVN) opened at 84.85 on Monday. Medivation has a 1-year low of $48.15 and a 1-year high of $88.20. The stock has a 50-day moving average of $76.87 and a 200-day moving average of $71.83. The company has a market cap of $6.515 billion and a price-to-earnings ratio of 270.80.

Medivation (NASDAQ:MDVN) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.36. The company had revenue of $148.09 million for the quarter, compared to the consensus estimate of $126.46 million. During the same quarter in the previous year, the company posted ($0.07) earnings per share. The company’s revenue for the quarter was up 111.1% on a year-over-year basis. On average, analysts predict that Medivation will post $2.38 earnings per share for the current fiscal year.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.